Design, Synthesis, and Biological Evaluation of Ferulic Acid-Piperazine Derivatives Targeting Pathological Hallmarks of Alzheimer’s Disease
ACS Chemical Neuroscience · 2024
DOI: 10.1021/acschemneuro.4c00130 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Chemical Neuroscience, 2024. Verfasst von Gourav Singh und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (Banaras Hindu University), Rm # 123, Varanasi 221005, India. Hauptthemen laut MEDLINE: Alzheimer Disease, Cholinesterase Inhibitors, Coumaric Acids, Amyloid beta-Peptides. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 85 Literaturangaben. Gefördert von: Indian Council of Medical Research, Science and Engineering Research Board, Indian Institute of Technology (BHU) Varanasi.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer's disease (AD) is the most prevalent cause of dementia and is characterized by low levels of acetyl and butyrylcholine, increased oxidative stress, inflammation, accumulation of metals, and aggregations of Aβ and tau proteins. Current treatments for AD provide only symptomatic relief without impacting the pathological hallmarks of the disease. In our ongoing efforts to develop naturally inspired novel multitarget molecules for AD, through extensive medicinal chemistry efforts, we have developed 13a, harboring the key functional groups to provide not only symptomatic relief but also targeting oxidative stress, able to chelate iron, inhibiting NLRP3, and Aβ1-42 aggregation in various AD models. 13a exhibited promising anticholinesterase activity against AChE (IC50 = 0.59 ± 0.19 μM) and BChE (IC50 = 5.02 ± 0.14 μM) with excellent antioxidant properties in DPPH assay (IC50 = 5.88 ± 0.21 μM) over ferulic acid (56.49 ± 0.62 μM). The molecular docking and dynamic simulations further corroborated the enzyme inhibition studies and confirmed the stability of these complexes. Importantly, in the PAMPA-BBB assay, 13a turned out to be a promising molecule that can efficiently cross the blood-brain barrier. Notably, 13a also exhibited iron-chelating properties. Furthermore, 13a effectively inhibited self- and metal-induced Aβ1-42 aggregation. It is worth mentioning that 13a demonstrated no symptom of cytotoxicity up to 30 μM concentration in PC-12 cells. Additionally, 13a inhibited the NLRP3 inflammasome and mitigated mitochondrial-induced reactive oxygen species and mitochondrial membrane potential damage triggered by LPS and ATP in HMC-3 cells. 13a could effectively reduce mitochondrial and cellular reactive oxygen species (ROS) in the Drosophila model of AD. Finally, 13a was found to be efficacious in reversing memory impairment in a scopolamine-induced AD mouse model in the in vivo studies. In ex vivo assessments, 13a notably modulates the levels of superoxide, catalase, and malondialdehyde along with AChE and BChE. These findings revealed that 13a holds promise as a potential candidate for further development in AD management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (Banaras Hindu University), Rm # 123, Varanasi 221005, India.
- Department of Pharmacology & Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Guwahati, Assam 781032, India.
- Department of Biophysics, All India Institute of Medical Sciences, New Delhi 110029, India.
- Department of Biochemistry, Institute of Sciences, Banaras Hindu University, Varanasi 201005, India.
ORCID-Profile: Yash Pal Singh, Saripella Srikrishna, Gyan Modi
Förderung
- Indian Council of Medical Research
- Science and Engineering Research Board
- Indian Institute of Technology (BHU) Varanasi
- Ministry of Education, India
Zitieren
APA
Singh, G., Kumar, S., Panda, S. R., Kumar, P., Rai, S., Verma, H., Singh, Y. P., Kumar, S., Srikrishna, S., Naidu, V. G. M., & Modi, G. (2024). Design, Synthesis, and Biological Evaluation of Ferulic Acid-Piperazine Derivatives Targeting Pathological Hallmarks of Alzheimer’s Disease. ACS Chemical Neuroscience. https://doi.org/10.1021/acschemneuro.4c00130
Vancouver
Singh G, Kumar S, Panda SR, Kumar P, Rai S, Verma H, et al. Design, Synthesis, and Biological Evaluation of Ferulic Acid-Piperazine Derivatives Targeting Pathological Hallmarks of Alzheimer’s Disease. ACS Chemical Neuroscience. 2024. doi:10.1021/acschemneuro.4c00130
BibTeX
@article{Singh2024,
author = {Singh, Gourav and Kumar, Sunil and Panda, Samir Ranjan and Kumar, Prabhat and Rai, Sanskriti and Verma, Himanshu and Singh, Yash Pal and Kumar, Saroj and Srikrishna, Saripella and Naidu, V G M and Modi, Gyan},
title = {Design, Synthesis, and Biological Evaluation of Ferulic Acid-Piperazine Derivatives Targeting Pathological Hallmarks of Alzheimer’s Disease},
journal = {ACS Chemical Neuroscience},
year = {2024},
doi = {10.1021/acschemneuro.4c00130}
}
EUVIMED